StabiEL: Stabilization of skin condition with Elidel - A patients' satisfaction observational study addressing the treatment, with pimecrolimus cream, of atopic dermatitis pretreated with topical corticosteroid

Journal of the European Academy of Dermatology and Venereology

Volumn 22, Issue 11, 2008, Pages 1319-1325

  Gollnick, Harald ^a   Luger, Thomas ^b   Freytag, Siegfried ^c   Bräutigam, Matthias ^d,e  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b UNIVERSITY OF MÜNSTER   (Germany)

^c TNS Healthcare GmbH   (Germany)

^d Novartis Pharma   (Germany)

^e Novartis Pharma GmbH   (Germany)

Author keywords

Atopic dermatitis; Atopic eczema; Eczema; Pimecrolimus; Skin stabilization; Topical corticosteroids

Indexed keywords

CORTICOSTEROID; PIMECROLIMUS;

ADULT; ARTICLE; ATOPIC DERMATITIS; BURN; CANDIDIASIS; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; ECZEMA; ERYTHEMA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT SATISFACTION; PRIORITY JOURNAL; PRURITUS; SKIN ATROPHY; STOMACH CANCER;

ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; CHILD; DERMATITIS, ATOPIC; DERMATOLOGIC AGENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; PATIENT SATISFACTION; QUESTIONNAIRES; RETROSPECTIVE STUDIES; TACROLIMUS;

EID: 53749104241     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2008.02807.x     Document Type: Article

References (27)

1. Wellington K, Jarvis B. Topical pimecrolimus. A review of its clinical potential in the management of atopic dermatitis. Drugs 2002 62 : 817 840.
2. Gupta AK, Chow M. Pimecrolimus: A review. J Eur Acad Dermatol Venereol 2003 17 : 493 503.
3. Eichenfield LF, Beck L. Elidel (pimecrolimus) cream 1%. a non-steroidal topical agent for the treatment of atopic dermatitis. J Allergy Clin Immunol 2003 111 : 1154 1168.
4. Wahn U, Bos JD, Goodfield M et al. for the Free (Children) Multicenter Investigator Group. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics 2002 110 : e2.
5. Papp KA, Werfel T, Fölster-Holst R et al. Long-term control of atopic dermatitis with pimecrolimus cream 1% in infants: a 2-year study. J Am Acad Dermatol 2005 52 : 240 246.
6. Meurer M, Fartasch M, Albrecht G et al. Long-term efficacy and safety of pimecrolimus cream 1% in adults with moderate atopic dermatitis. Dermatology 2004 208 : 365 372.
7. Kapp A, Papp K, Bingham A et al. Efficacy and safety of pimecrolimus cream, a novel non-steroid anti-inflammatory, in long-term management of atopic dermatitis in infants. J Allergy Clin Immunol 2002 110 : 277 278.
8. Luebbe J, Friedlander SF, Cribier B et al. Safety, efficacy, and dosage of 1% pimecrolimus cream for the treatment of atopic dermatitis in daily practice. Am J Clin Dermatol 2006 7 : 121 131.
9. Ring J, Abraham A, de Cuyper C et al. Control of atopic eczema with pimecrolimus cream 1% under daily practice conditions: results of a >2000 patient study. J Eur Acad Dermatol Venereol 2007 : 22 : 195 203 doi:.
10. Lakhanpaul M, Davies T, Allen BR, Schneider D. Low systemic exposure in infants with atopic dermatitis in a 1-year pharmacokinetic study with pimecrolimus cream 1%. Exp Dermatol 2006 15 : 138 141.
11. Staab D, Pariser D, Gottlieb AB et al. Low systemic absorption and good tolerability of pimecrolimus administered as 1% cream (Elidel®) in infants with atopic dermatitis - A multicenter, 3-week, open-label study. Pediatric Dermatol 2005 22 : 465 471.
12. Queille-Roussel C, Paul C, Duteil L et al. The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double-blind controlled study. Br J Dermatol 2001 144 : 507 513.
13. Van Leent EJM, Ebelin ME, Burtin P, Dorobek B, Spuls PI, Bos JD. Low systemic exposure after repeated topical application of pimecrolimus (Elidel®, SDZ ASM 981) in patients with atopic dermatitis. Dermatology 2002 204 : 63 68.
14. Grassberger M, Steinhoff M, Schneider D, Luger T. Pimecrolimus - an anti-inflammatory drug targeting the skin. J Exp Dermatol 2004 13 : 721 730.
15. Billich A, Aschauer H, Aszody A, Stuetz A. Pimecrolimus permeates less through skin than corticosteroids and tacrolimus. Int J Pharm 2004 269 : 29 35.
16. Cork M, Robinson D, Vasilopoulos Y, Ferguson A. Interaction of topical corticosteroids and pimecrolimus with the skin barrier. Implications for efficacy and safety of treatment for atopic dermatitis (conference abstract). J Am Acad Dermatol 2006 : 54 (Suppl. S AB3 P10.
17. Gollnick H, Luger T, Bräutigam M. Safety and efficacy of pimecrolimus cream 1% in daily practice, with a retrospective comparison with prior treatments: An observational study. EADV Vienna 2008. Abstracts CD-ROM Poster 1324. ISBN 978-3-940017-07-9/2007.
18. Sunderkötter C, Weiss JM, Bextermöller R, Löffler H, Schneider D. Post-marketing surveillance on treatment of 5,665 patients with atopic dermatitis using the calcineurin inhibitor pimecrolimus: Positive effects on major symptoms of atopic dermatitis and on quality of life. JDDG 2006 4 : 301 307.
19. Luger TA, Gollnick H, Schwennesen T, Bextermöller R, Freytag S, Bräutigam M. Safety and efficacy of pimecrolimus cream 1 % in the daily practice: Results of a patient self-observation study in patients with atopic dermatitis. JDDG 2007; 5: 908-915 doi:.
20. Vergnanini AL, Aoki V, Takaoka R, Madi J. Comparative effects of pimecrolimus cream vehicle and three commercially available moisturizers on skin hydration and transepidermal water loss. J Am Acad Dermatol 2007 56 (Suppl. 2 AB60.
21. Charman CR, Morris AD, Williams HC. Topical corticosteroid phobia in patients with atopic eczema. Br J Dermatol 2000 142 : 931 936.
22. Zuberbier T, Orlow SJ, Paller AS et al. Patients perspectives on the management of atopic dermatitis. J Allergy Clin Immunol 2006 118 : 226 232.
23. Elias PM, Feingold KR. Does the tail wag the dog? Role of the barrier in the pathogenesis of inflammatory dermatoses and therapeutic implications. Arch Dermatol 2001 137 : 1079 1081.
24. Sheu HM, Lee JY, Chai CY, Kuo KW. Depletion of stratum corneum intercellular lipid lamellae and barrier function abnormalities after long-term topical corticosteroids. Br J Dermatol 1997 136 : 884 890.
25. Cork M, Robinson D, Vasipopoulos Y, Ferguson A. The effects of topical corticosteroids and pimecrolimus skin barrier function, gene expression, and topical drug penetration in atopic eczema and unaffected controls. J Am Acad Dermatol 2007 AB69 : P708.
26. Proksch E, Jensen JM, Elias P, Folster-Holst R. Substantial improvement of the skin barrier in atopic dermatitis after treatment with pimecrolimus but not with betamethasone. J Am Acad Dermatol 2007 AB3 : P9.
27. Breuer K, Bräutigam M, Kapp A, Werfel T. Influence of pimecrolimus cream 1 % on different morphological signs of eczema in infants with atopic dermatitis. Dermatology 2004 209 : 314 320.